Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
Ferrari M, Mekkaoui L, Ilca FT, Akbar Z, Bughda R, Lamb K, Ward K, Parekh F, Karattil R, Allen C, Wu P, Baldan V, Mattiuzzo G, Bentley EM, Takeuchi Y, Sillibourne J, Datta P, Kinna A, Pule M, Onuoha SC.
Ferrari M, et al. Among authors: mattiuzzo g.
J Virol. 2021 Sep 9;95(19):e0068521. doi: 10.1128/JVI.00685-21. Epub 2021 Sep 9.
J Virol. 2021.
PMID: 34287040
Free PMC article.